Persistent organic pollutants, mitochondrial dysfunction, and metabolic syndrome

Annals of the New York Academy of Sciences

Volumn 1201, Issue , 2010, Pages 166-176

  Lim, Soo ^a,b   Cho, Young Min ^a   Park, Kyong Soo ^a   Lee, Hong Kyu ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Eulji University   (South Korea)

Author keywords

insulin resistance; metabolic syndrome; mitochondrial dysfunction; persistent organic pollutants

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 3 NITROPROPIONIC ACID; 4,4' ISOPROPYLIDENEDIPHENOL; ADIPONECTIN; ADIPONECTIN RECEPTOR; ARSENIC; ATRAZINE; HEXACHLOROBENZENE; I KAPPA B KINASE BETA; MITOCHONDRIAL DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REACTIVE OXYGEN METABOLITE; ORGANIC COMPOUND;

ATHEROSCLEROSIS; CELL DAMAGE; CONFERENCE PAPER; DISEASE ASSOCIATION; ENDOPLASMIC RETICULUM STRESS; GENOTYPE PHENOTYPE CORRELATION; HEREDITY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; METABOLIC SYNDROME X; MITOCHONDRIAL DNA DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; OUTCOME ASSESSMENT; OXIDATIVE PHOSPHORYLATION; PERSISTENT ORGANIC POLLUTANTS; POLLUTANT; PREGNANCY DIABETES MELLITUS; RESPIRATORY CHAIN; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOPLASMIC RETICULUM; INFLAMMATION; METABOLISM; MITOCHONDRION; OXIDATIVE STRESS; PATHOLOGY; REVIEW;

ADIPONECTIN; ANIMALS; DNA, MITOCHONDRIAL; ENDOPLASMIC RETICULUM; ENVIRONMENTAL POLLUTANTS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MODELS, BIOLOGICAL; ORGANIC CHEMICALS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 77955290804     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05622.x     Document Type: Conference Paper

References (89)

1. Meigs, J.B. 2000. Invited commentary: insulin resistance syndrome Syndrome X Multiple metabolic syndrome A syndrome at all Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am. J. Epidemiol. 152: 908-911.
2. Shen,S.W., G.M.Reaven & J.W. Farquhar. 1970.Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J. Clin. Invest. 49: 2151-2160.
3. Ames, B.N., M.K. Shigenaga & T.M.Hagen. 1993. Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. USA 90: 7915-7922.
4. Lamb, R.E. & B.J. Goldstein. 2008.Modulating an oxidativeinflammatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function. Int. J. Clin. Pract. 62: 1087-1095.
5. Goldstein, B.J., K.Mahadev & X.Wu. 2005. Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes 54: 311-321.
6. Schulz, T.J. et al. 2007. Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. Cell. Metab. 6: 280-293.
7. Hotamisligil, G.S., N.S. Shargill & B.M. Spiegelman. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259: 87-91.
8. Wellen,K.E. & G.S.Hotamisligil. 2005. Inflammation, stress, and diabetes. J. Clin. Invest. 115: 1111-1119.
9. Kadowaki, T. et al. 2006. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116: 1784-1792.
10. Weyer, C. et al. 2001. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 86: 1930-1935.
11. Spranger, J. et al. 2003. Adiponectin and protection against type 2 diabetes mellitus. Lancet 361: 226-228.
12. Matsuzawa, Y. et al. 2004. Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 24: 29-33.
13. Lindsay, R.S. et al. 2002. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360: 57-58.
14. Sharma, N.K. et al. 2008. Endoplasmic reticulum stress markers are associated with obesity in nondiabetic subjects. J. Clin. Endocrinol. Metab. 93: 4532-4541.
15. Boden, G. et al. 2008. Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. Diabetes 57: 2438-2444.
16. Ozcan, U. et al. 2004. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306: 457-461.
17. Yerneni, K.K. et al. 1999. Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes 48: 855-864.
18. Kim, A.J. et al. 2005. Valproate protects cells from ER stressinduced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J. Cell. Sci. 118: 89-99.
19. Gregor, M.F. & G.S. Hotamisligil. 2007. Thematic review series: adipocyte biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J. Lipid. Res. 48: 1905-1914.
20. Yoshiuchi, K. et al. 2009. Pioglitazone reduces ER stress in the liver: direct monitoring of in vivo ER stress using ER stress-activated indicator transgenic mice. Endocr. J. 56: 1103-1111.
21. Eckardt, K., H. Sell & J. Eckel. 2008. Novel aspects of adipocyte-induced skeletal muscle insulin resistance. Arch. Physiol. Biochem. 114: 287-298.
22. Petersen, K.F. & G.I. Shulman. 2002. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am. J. Cardiol. 90: 11G-18G.
23. Lara-Castro, C. & W.T. Garvey. 2008. Intracellular lipid accumulation in liver and muscle and the insulin resistance syndrome. Endocrinol. Metab. Clin. North Am. 37: 841-856.
24. Frojdo, S., H. Vidal & L. Pirola. 2009. Alterations of insulin signaling in type 2 diabetes: a review of the current evidence from humans. Biochim. Biophys. Acta. 1792: 83-92.
25. Bogacka, I. et al. 2005. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 54: 1392-1399.
26. Semple, R.K. et al. 2004. Expression of the thermogenic nuclear hormone receptor coactivator PGC-1alpha is reduced in the adipose tissue ofmorbidly obese subjects. Int. J. Obes. Relat. Metab. Disord. 28: 176-179.
27. Lowell, B.B. & G.I. Shulman. 2005. Mitochondrial dysfunction and type 2 diabetes. Science 307: 384-387.
28. Abdul-Ghani, M.A. & R.A. DeFronzo. 2008. Mitochondrial dysfunction, insulin resistance, and type 2 diabetesmellitus. Curr. Diab. Rep. 8: 173-178.
29. Morino, K. et al. 2005. Reduced mitochondrial density and increased IRS-1 serine phosphorylation inmuscle of insulinresistant offspring of type 2 diabetic parents. J. Clin. Invest. 115: 3587-3593.
30. Park, K.S. et al. 1999. Peripheral blood mitochondrial DNA content correlates with lipid oxidation rate during euglycemic clamps in healthy young men. Diabetes Res. Clin. Pract. 46: 149-154.
31. Wang, H. et al. 1999. Relationships between muscle mitochondrial DNA content, mitochondrial enzyme activity and oxidative capacity in man: alterations with disease. Eur. J. Appl. Physiol Occup. Physiol 80: 22-27.
32. Lee, H.K. et al. 1998. Decreased mitochondrial DNA content in peripheral blood precedes the development of noninsulin-dependent diabetes mellitus. Diabetes Res. Clin. Pract. 42: 161-167.
33. Park, K.S. et al. 1999. Peripheral blood mitochondrial DNA content correlates with lipid oxidation rate during euglycemic clamps in healthy young men. Diabetes Res. Clin. Pract. 46: 149-154.
34. Song, J. et al. 2001. Peripheral blood mitochondrial DNA content is related to insulin sensitivity in offspring of type 2 diabetic patients. Diabetes Care 24: 865-869.
35. Lim, S. et al. 2000. Effect of exercise on the mitochondrial DNA content of peripheral blood in healthy women. Eur. J. Appl. Physiol. 82: 407-412.
36. Morino, K., K.F. Petersen & G.I. Shulman. 2006. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55(Suppl. 2): S9-S15.
37. Petersen, K.F. et al. 2003. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300: 1140-1142.
38. Itani, S.I. et al. 2002. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 51: 2005-2011.
39. Griffin,M.E. et al. 1999. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48: 1270-1274.
40. Yu, C. et al. 2002. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277: 50230-50236.
41. Kim, J.K. et al. 2004. PKC-theta knockoutmice are protected from fat-induced insulin resistance. J. Clin. Invest. 114: 823-827.
42. Handschin, C. et al. 2007. Abnormal glucose homeostasis in skeletal muscle-specific PGC-1alpha knockout mice reveals skeletal muscle-pancreatic beta cell crosstalk. J. Clin. Invest. 117: 3463-3474.
43. Park, S.Y. et al. 2005. Depletion of mitochondrial DNA causes impaired glucose utilization and insulin resistance in L6 GLUT4myc myocytes. J. Biol. Chem. 280: 9855-9864.
44. Ling, C. et al. 2004. Multiple environmental and genetic factors influence skeletal muscle PGC-1alpha and PGC-1beta gene expression in twins. J. Clin. Invest. 114: 1518-1526.
45. Cho, Y.M., K.S. Park & H.K. Lee. 2007. Genetic factors related to mitochondrial function and risk of diabetes mellitus. Diabetes Res. Clin. Pract. 77(Suppl. 1): S172-S177.
46. Poulton, J. et al. 1998. A commonmitochondrial DNA variant is associated with insulin resistance in adult life. Diabetologia 41: 54-58.
47. Poulton, J. et al. 2002. Type 2 diabetes is associated with a common mitochondrial variant: evidence from a population-based case-control study. Hum. Mol. Genet. 11: 1581-1583.
48. Park, K.S. et al. 2008. A mitochondrial DNA variant at position 16189 is associated with type 2 diabetes mellitus in Asians. Diabetologia 51: 602-608.
49. Das, S. et al. 2007. Detailed analysis of variation at and around mitochondrial position 16189 in a large Finnish cohort reveals no significant associations with early growth or metabolic phenotypes at age 31 years. J. Clin. Endocrinol. Metab. 92: 3219-3223.
50. Chinnery, P.F. et al. 2005. Role of the mitochondrial DNA 16184-16193 poly-C tract in type 2 diabetes. Lancet 366: 1650-1651
51. Cho, Y.M. et al. 2005. Association between polymorphisms in the nuclear respiratory factor 1 gene and type 2 diabetes mellitus in the Korean population. Diabetologia 48: 2033-2038.
52. 't Hart, L.M. et al. 2005. Evidence that the mitochondrial leucyl tRNA synthetase (LARS2) gene represents a novel type 2 diabetes susceptibility gene. Diabetes 54: 1892-1895.
53. McCance, D.R. et al. 1994. Birth weight and non-insulin dependent diabetes: thrifty genotype, thrifty phenotype, or surviving small baby genotype? BMJ 308: 942-945.
54. Hales, C.N. & D.J. Barker. 1992. Type 2 (non-insulindependent) diabetesmellitus: the thrifty phenotype hypothesis. Diabetologia 35: 595-601.
55. Lee, Y.Y. et al. 2005. The role of mitochondrial DNA in the development of type 2 diabetes caused by fetal malnutrition. J. Nutr. Biochem. 16: 195-204.
56. Neel, J.V. 1999. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? 1962. Bull. World Health Organ. 77: 694-703.
57. Hattersley, A.T. & J.E. Tooke. 1999. The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. Lancet 353: 1789-1792.
58. McGarry, J.D. 2002. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51: 7-18.
59. Anderson, E.J. et al. 2009. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J. Clin. Invest. In press. doi: 10.1172/JCI37048.
60. Sutherland, L.N. et al. 2008. Time course of high-fat dietinduced reductions in adipose tissue mitochondrial proteins: potential mechanisms and the relationship to glucose intolerance. Am. J. Physiol. Endocrinol. Metab. 295: E1076-E1083.
61. Black, A.E. et al. 1996.Humanenergy expenditure in affluent societies: an analysis of 574 doubly-labelled water measurements. Eur. J. Clin. Nutr. 50: 72-92.
62. Laufs, U. et al. 2005. Physical inactivity increases oxidative stress, endothelial dysfunction, and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25: 809-814.
63. Coronado-Gonzalez, J.A. et al. 2007. Inorganic arsenic exposure and type 2 diabetes mellitus inMexico. Environ. Res. 104: 383-389.
64. Navas-Acien, A. et al. 2008. Arsenic exposure and prevalence of type 2 diabetes in US adults. JAMA 300: 814-822.
65. Lee, D.H. et al. 2007. Association between serum concentrations of persistent organic pollutants and insulin resistance among nondiabetic adults: results from the National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 30: 622-628.
66. Lee, D. H. et al. 2006. A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Examination Survey 1999-2002. Diabetes Care 29: 1638-1644.
67. Pelletier, C., J.P. Despres & A. Tremblay. 2002. Plasma organochlorine concentrations in endurance athletes and obese individuals. Med. Sci. Sports Exerc. 34: 1971-1975.
68. Lim, S. et al. 2009. Chronic exposure to the herbicide, atrazine, causes mitochondrial dysfunction and insulin resistance. PLoS One 4: e5186. doi: 10.1371/ journal.pone.0005186.
69. Ruzzin, J. et al. 2010. Persistent organic pollutant exposure leads to insulin resistance syndrome. Environ. Health Perspect. 118: 465-471.
70. Ha,M.H. et al. 2009. Association between serumconcentrations ofpersistent organic pollutants and prevalence ofnewly diagnosed hypertension: results from the National Health and Nutrition Examination Survey 1999-2002. J. Hum. Hypertens. 23: 274-286.
71. Chevrier, J. et al. 2000. Bodyweight loss increases plasma and adipose tissue concentrations of potentially toxic pollutants in obese individuals. Int. J. Obes. Relat. Metab. Disord. 24: 1272-1278.
72. Imbeault, P. et al. 2002. Weight loss-induced rise in plasma pollutant is associated with reduced skeletal muscle oxidative capacity. Am. J. Physiol. Endocrinol. Metab. 282: E574-E579.
73. Tremblay, A. et al. 1999.Metabolic fitness in active reducedobese individuals. Obes. Res. 7: 556-563.
74. Lim, S. et al. 2009. Fat in liver/muscle correlates more strongly with insulin sensitivity in rats than abdominal fat. Obesity (Silver Spring) 17: 188-195.
75. Tsutsumi, T. et al. 2003. Validation of the CALUX bioassay for the screening of PCDD/Fs and dioxin-like PCBs in retail fish. Analyst 128: 486-492.
76. Kim, J.A., Y. Wei & J.R. Sowers. 2008. Role of mitochondrial dysfunction in insulin resistance. Circ. Res. 102: 401-414.
77. Pelletier, C., P. Imbeault & A. Tremblay. 2003. Energy balance and pollution by organochlorines and polychlorinated biphenyls. Obes. Rev. 4: 17-24.
78. Montaner, J.S. et al. 2003.Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy. J. Acquir. Immune. Defic. Syndr. 34(Suppl. 1): S85-S90.
79. Wand, H. et al. 2007. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 21: 2445-2453.
80. Saldana, T.M. et al. 2007. Pesticide exposure and selfreported gestational diabetes mellitus in the Agricultural Health Study. Diabetes Care 30: 529-534.
81. Hugo, E.R. et al. 2008. Bisphenol A at environmentally relevant doses inhibits adiponectin release from human adipose tissue explants and adipocytes. Environ.Health Perspect. 116: 1642-1647.
82. Ben-Jonathan, N., E.R. Hugo & T.D. Brandebourg. 2009. Effects of bisphenol A on adipokine release from human adipose tissue: implications for the metabolic syndrome. Mol. Cell Endocrinol. 304: 49-54.
83. Rubin, B.S. & A.M. Soto. 2009. Bisphenol A: perinatal exposure and body weight. Mol. Cell Endocrinol. 304: 55-62.
84. Lang, I.A. et al. 2008. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 300: 1303-1310.
85. Hokanson, R. et al. 2004. Disruption of estrogen-regulated gene expression by dioxin: downregulation of a gene associated with the onset of non-insulin-dependent diabetes mellitus (type 2 diabetes). Hum. Exp. Toxicol. 23: 555-564.
86. Pelclova, D. et al. 2006. Adverse health effects in humans exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Rev. Environ. Health. 21: 119-138.
87. Klivenyi, P. et al. 2005. Effects of mitochondrial toxins on the brain amino acid concentrations. Neurochem. Res. 30: 1421-1427.
88. Paul, D.S. et al. 2007.Molecularmechanisms of the diabetogenic effects of arsenic: inhibition of insulin signaling by arsenite and methylarsonous acid. Environ. Health Perspect. 115: 734-742.
89. Salazard, B. et al. 2004. Low-level arsenite activates the transcription of genes involved in adipose differentiation. Cell Biol. Toxicol. 20: 375-385.